ImmunoCellular Therapeutics, Ltd. announced the resignation of Dr. John Yu as Chief Scientific Officer, effective October 1, 2015. Dr. Yu will remain a member of the board of directors of the company, but will no longer serve as chairman. Dr. Yu will continue to provide services to the company pursuant to a consulting agreement, effective October 1, 2015.

Pursuant to the Agreement, Dr. Yu will provide consulting services to the company, including supporting the execution of the phase 3 clinical trial of ICT-107 and assisting with the evaluation and acquisition of outside technology.